What Happened?
San Francisco, CA-based Excision BioTherapeutics Appointed Franz Gerner as Chief Technology Officer
About the Company
Excision BioTherapeutics is a private company focused on developing advanced gene editing therapeutics to address the medical need for the treatment of life-threatening disease caused by viral infections. Our mission is to advance gene editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.
About the Person
Franz Gerner is Chief Technology Officer at Excision BioTherapeutics. Previously, Franz held various senior IT leadership roles in the industry.
Info Source
News
Short Profile